Question explored with the scientific record
Conversation so far
- 1 As a 74 year old, healthy otherwise, i no have Long Covod for 8 months. Is ther a way out of it?
- 2 What is the timeframe for getting over it
- 3 Are there factors (severity, labs, imaging) that predict recovery time?
- 4 What symptom-specific scores or tests are best for tracking improvement?
Answered on this page ↓
What symptom-specific scores or tests are best for tracking improvement?
The short version: symptom-specific validated scales and objective biomarkers both track improvement, but the evidence is thin on which combination best predicts recovery trajectory.
The evidence retrieved shows that several validated scales are used to track specific symptoms in long COVID. The mMRC dyspnea scale and Fatigue Assessment Scale (FAS) were used in a 2023 prospective cohort of 669 adults to predict long-COVID risk at 90 days [3]. The SF-12 health survey, HADS for anxiety and depression, and mMRC were used in a 2025 longitudinal study of 50 adults to track improvement after an adapted physical activity program [4]. That study found large effect sizes: SF-12 global score rose from 35.2 to 48.6 (eta²=0.68), HADS-A fell from 10.2 to 6.1 (eta²=0.62), and dyspnea prevalence dropped from 86% to 52% [4]. The DePaul Symptom Questionnaire was used in a 2022 cross-sectional survey of 299 adults to classify PASC severity and found that 74-89% of severely impaired participants met ME/CFS criteria [16].
Objective biomarkers also correlate with symptom severity. A 2025 study of 120 recovered patients found that IL-6, CRP, and MDA levels correlated with fatigue scores (r=0.69, 0.65, 0.61 respectively) [11]. A 2025 study of 14 long-COVID patients with cardiovascular symptoms found persistent mitochondrial dysfunction in monocytes, with 80% mtDNA depletion and blunted oxidative stress response [9]. The 6-minute walk test and DLCO were used as objective measures in a 2026 study of 1011 hospitalized patients, with dexamethasone associated with better DLCO (76.9% vs 69.9% predicted) and longer walk distance (435m vs 405m) [6].
| Tracking method | What it measures | Evidence strength |
|---|---|---|
| mMRC dyspnea scale | Breathlessness | Used in multiple cohorts [3, 4, 14] |
| SF-12 / SF-20 | Physical and mental health status | Large effect sizes in intervention study [4] |
| HADS-A / HADS-D | Anxiety and depression | Responsive to change [4] |
| IL-6, CRP, MDA | Inflammation and oxidative stress | Correlate with fatigue (r=0.61-0.69) [11] |
| 6-minute walk test | Functional exercise capacity | Differentiates treatment groups [6] |
| DLCO | Lung gas exchange | Objective pulmonary measure [6] |
My call: symptom-specific validated scales (mMRC, SF-12, HADS) and objective biomarkers (IL-6, CRP, 6MWT, DLCO) both track improvement, but no study in this retrieval directly compared which combination best predicts recovery trajectory over time. Confidence: low — the evidence shows these tools work individually but does not answer the comparative question.
Sources examined 16
-
COVID-19 disease severity to predict persistent symptoms: a systematic review and meta-analysis
Initial COVID-19 disease severity is linked to higher risk of persistent dyspnea and fatigue, but generally not to most other long-COVID symptoms, across post-acute and long-COVID periods.
DOI: 10.1017/s1463423622000585 -
Post-COVID-19 Condition and Health Status
A two-time telephone follow-up (roughly 1 and 3 months post-discharge) observational study of 40 adults recovering from COVID-19, assessing broad health status and symptom trajectories using SF-20 and related instruments, finding persistent impairments with dyspnea emerging as a…
DOI: 10.3390/covid2010006 -
A prospective cohort study assessing the relationship between long-COVID symptom incidence in COVID-19 patients and COVID-19 vaccination
A prospective cohort of 669 adults with confirmed COVID-19 followed for 90 days to determine the incidence of long-COVID and to identify associated risk factors, finding a 41.6% incidence with higher risk among females, older individuals, hospitalized patients, those with early …
DOI: 10.1038/s41598-023-30583-2 -
Adapted Physical Activity Protocol Improves Health-Related Quality of Life and Psychological Outcomes in Long COVID: A Prospective Longitudinal Study
A prospective longitudinal, single-center study in Tunisia evaluating a 6-week Adapted Physical Activity (APA) program for 50 adults with long COVID, showing significant short- and mid-term improvements in health-related quality of life and psychological outcomes (anxiety/depres…
DOI: 10.2147/jmdh.s530582 -
A Scoping Review on Long COVID-19: Physiological and Psychological Symptoms Post-Acute, Long-Post and Persistent Post COVID-19
A scoping review of long COVID-19 in 33 studies (2020–2022) mapping prevalence and patterns of physiological and psychological symptoms across phases, identifying risk factors, gaps, and implications for management.
DOI: 10.3390/healthcare10122418 -
Impact of Dexamethasone on Respiratory Sequelae in the Follow-Up of Hospitalized Patients with Sars-Cov-2 Pneumonia
Dexamethasone during hospitalization for severe COVID-19 pneumonia is associated with improved post-COVID respiratory outcomes, including less dyspnea, better diffusion capacity (DLCO), greater 6-minute walk distance, and fewer radiologic signs of fibrosis at 3–9 months after di…
DOI: 10.2147/IDR.S547449 -
Remotely delivered weight management for people with long COVID and overweight: the randomized wait-list-controlled ReDIRECT trial
Remotely delivered structured weight management for overweight adults with long COVID produced substantial weight loss (~10 kg) and meaningful improvement in participants’ self-selected primary LC symptoms at 6 months, with acceptable safety, compared with a wait-list control.
DOI: 10.1038/s41591-024-03384-x -
The Impact of Long COVID on Global Public Health: Long-term Consequences and Healthcare System Preparedness
A multinational cross-sectional study of 5,000 individuals with Long COVID across income regions that quantifies prevalence, symptom profiles, quality of life, healthcare utilization, and the preparedness of healthcare systems, revealing a 30% prevalence, substantial functional …
DOI: 10.37899/mjdh.v1i2.74 -
Persistent Monocytic Bioenergetic Impairment and Mitochondrial DNA Damage in PASC Patients with Cardiovascular Complications
In long-COVID patients with cardiovascular symptoms, CD14++ monocytes display persistent mitochondrial dysfunction with impaired oxidative stress adaptation, massive mtDNA depletion and region-specific mtDNA damage, linking monocytic bioenergetic failure to cardiovascular sequel…
DOI: 10.3390/ijms26104562 -
Long COVID: A Comprehensive Overview of the Signs and Symptoms across Multiple Organ Systems
This study provides a comprehensive overview of the signs and symptoms of Long COVID across multiple organ systems, highlighting the complexity and variability of post-acute sequelae of COVID-19.
DOI: 10.4082/kjfm.24.0085 -
Post-Acute COVID-19 Pathophysiology: Cellular Stress Responses, Immune Dysregulation, and Biochemical Signatures in Recovery Phase
The study investigates post-acute COVID-19 pathophysiology by integrating cellular ER stress markers, immune dysregulation, and oxidative/biochemical signatures in recovered patients, revealing persistent cellular stress, pro-inflammatory cytokine elevation, and oxidative imbala…
DOI: 10.33594/000000795 -
1136 Sleep Disorders in Children and Adolescents with Long COVID
A cross-sectional pilot study in adults examining how sleep disturbances and REM sleep percentage relate to post-COVID syndrome (PASC) symptoms, finding that lower REM sleep is tied to greater sleep disturbance and uncovering subgroup differences in sleep-related autonomic activ…
DOI: 10.1093/sleep/zsae067.01136 -
Characteristics and predictors of acute and chronic post-COVID syndrome: A systematic review and meta-analysis
This study systematically reviews and meta-analyzes published data to characterize the clinical features of acute and chronic post-COVID syndrome (post-COVID/long-COVID), identifies predictors of syndrome development, and highlights the substantial heterogeneity and generally po…
DOI: 10.1016/j.eclinm.2021.100899 -
“Long COVID” results after hospitalization for SARS-CoV-2 infection
This prospective cohort study of 471 hospitalized COVID-19 patients in Italy found that 30.3% (6 months) and 25.3% (12 months) had persistent symptoms after discharge, with patients requiring non-invasive or invasive ventilation during hospitalization having significantly higher…
DOI: 10.1038/s41598-022-13077-5 -
Impact of psychological intervention on anxiety, depression, and post-traumatic stress disorder: results from a longitudinal study of hospitalized Covid-19 patients
In a naturalistic longitudinal follow-up of hospitalized COVID-19 patients, psychological intervention was more often chosen by those with greater distress, and while longer psychological support may stabilize depressive symptoms, anxiety and PTSD tended to rise over 12 months, …
DOI: 10.1708/4288.42696 -
A CLASSIFICATION SYSTEM FOR POST-ACUTE SEQUELAE OF SARS CoV-2 INFECTION
A cross-sectional survey of 299 adults with post-acute sequelae of SARS-CoV-2 (PASC) who had not recovered from COVID-19 used the DePaul Symptom Questionnaire to show that the proportion meeting an ME/CFS case definition increased with functional impairment severity (0% mild, 30…
DOI: 10.47316/cajmhe.2022.3.1.04